Table 2 Efficacy results.

From: Nanoliposomal irinotecan with fluorouracil and folinic acid, FOLFIRINOX, and S-1 as second-line treatment for unresectable pancreatic cancer after gemcitabine/nab-paclitaxel

 

NFF (n = 102)

S-1 (n = 57)

FOLFIRINOX (n = 14)

P-value

Best overall response, n (%)

 CR

0

0

0

 

 PR

5 (4.9)

1 (1.8)

0

 

 SD

44 (43.1)

11 (19.3)

6 (42.9)

 

 PD

44 (43.1)

33 (57.9)

7 (50.0)

 

 NE

9 (8.8)

12 (21.1)

1 (7.1)

 

ORR (CR + PR), n (%)

5 (4.9)

1 (1.8)

0

0.654

DCR (CR + PR + SD), n (%)

49 (48.0)

12 (21.1)

6 (42.9)

0.002

  1. NFF nanoliposomal irinotecan with fluorouracil and folinic acid, CR complete response, PR partial response, SD stable disease, PD progressive disease, ORR overall response rate, DCR disease control rate.
Back to article page